DCTD and cancer: Deoxycytidylate deaminase, converting deoxycytidine monophosphate (dCMP) to dUMP, is an enzyme that supplies the vast majority of dUMP for cancer cells [41, 167], and cells with high expression of DCTD are better able to maintain dUMP pools when the de novo pyrimidine synthesis pathway is inhibited, suggesting that combination of DHODH and DCTD inhibitors maybe a significant antitumor strategy, though the utility requires further investigation [41, 168, 169].